---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-011831"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:47:30.295344+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences appoints Liane Teplitsky COO; expands Dr. Kenigsberg as full-time CMO

## Summary
- Liane Teplitsky named COO effective April 8, 2026; oversees Clinical, Regulatory, Quality, Commercial functions.
- Received inducement award: 700,000 stock options ($19.06) and 200,000 RSUs; vesting tied to market cap and revenue milestones.
- Dr. David Kenigsberg expands to full-time Chief Medical Officer, continues active practice; will lead IDE pivotal study for nPulse catheter.
- Two other new employees granted inducement options for 7,700 shares total at $19.06, time-vesting over four years.

## SEC filing metadata
- accession: 0001437749-26-011831
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774926011831/0001437749-26-011831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774926011831/plse20260316_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-011831
- JSON: https://secwatch.observer/filing/0001437749-26-011831.json
- Plain text: https://secwatch.observer/filing/0001437749-26-011831.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.